Murcko Mark 4
4 · Relay Therapeutics, Inc. · Filed Jul 21, 2020
Insider Transaction Report
Form 4
Murcko Mark
Director
Transactions
- Conversion
Common Stock
2020-07-20+281,617→ 718,123 total - Conversion
Common Stock
2020-07-20+278,829→ 996,952 total - Purchase
Common Stock
2020-07-20$20.00/sh+25,000$500,000→ 1,021,952 total - Conversion
Series A Convertible Preferred Stock
2020-07-20−1,000,000→ 0 total→ Common Stock (281,617 underlying) - Conversion
Series B Convertible Preferred Stock
2020-07-20−990,099→ 0 total→ Common Stock (278,829 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
- [F2]Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.
- [F3]On July 20, 2020, the reporting person purchased 25,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering.